<?xml version='1.0' encoding='utf-8'?>
<document id="27520758"><sentence text="Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells."><entity charOffset="20-30" id="DDI-PubMed.27520758.s1.e0" text="amiodarone" /></sentence><sentence text="Several clinical cases of severe bradyarrhythmias have been reported upon co-administration of the Hepatitis-C NS5B Nucleotide Polymerase Inhibitor (HCV-NI) direct-acting antiviral agent, sofosbuvir (SOF), and the Class-III anti-arrhythmic amiodarone (AMIO)"><entity charOffset="188-198" id="DDI-PubMed.27520758.s2.e0" text="sofosbuvir" /><entity charOffset="200-203" id="DDI-PubMed.27520758.s2.e1" text="SOF" /><entity charOffset="240-250" id="DDI-PubMed.27520758.s2.e2" text="amiodarone" /><entity charOffset="252-256" id="DDI-PubMed.27520758.s2.e3" text="AMIO" /><pair ddi="false" e1="DDI-PubMed.27520758.s2.e0" e2="DDI-PubMed.27520758.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27520758.s2.e0" e2="DDI-PubMed.27520758.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s2.e0" e2="DDI-PubMed.27520758.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s2.e0" e2="DDI-PubMed.27520758.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27520758.s2.e1" e2="DDI-PubMed.27520758.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s2.e1" e2="DDI-PubMed.27520758.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s2.e1" e2="DDI-PubMed.27520758.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27520758.s2.e2" e2="DDI-PubMed.27520758.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s2.e2" e2="DDI-PubMed.27520758.s2.e3" /></sentence><sentence text=" We model the cardiac drug-drug interaction (DDI) between AMIO and SOF, and between AMIO and a closely-related SOF analog, MNI-1 (Merck Nucleotide Inhibitor #1), in functional assays of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), to provide mechanistic insights into recently reported clinical cases"><entity charOffset="67-70" id="DDI-PubMed.27520758.s3.e0" text="SOF" /><entity charOffset="111-114" id="DDI-PubMed.27520758.s3.e1" text="SOF" /><entity charOffset="58-61" id="DDI-PubMed.27520758.s3.e2" text="AMIO" /><entity charOffset="84-87" id="DDI-PubMed.27520758.s3.e3" text="AMIO" /><pair ddi="false" e1="DDI-PubMed.27520758.s3.e2" e2="DDI-PubMed.27520758.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s3.e2" e2="DDI-PubMed.27520758.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27520758.s3.e2" e2="DDI-PubMed.27520758.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27520758.s3.e2" e2="DDI-PubMed.27520758.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s3.e0" e2="DDI-PubMed.27520758.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27520758.s3.e0" e2="DDI-PubMed.27520758.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27520758.s3.e0" e2="DDI-PubMed.27520758.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s3.e3" e2="DDI-PubMed.27520758.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27520758.s3.e3" e2="DDI-PubMed.27520758.s3.e1" /></sentence><sentence text=" AMIO co-applied with SOF or MNI-1 increased beating rate or field potential (FP) rate and decreased impedance (IMP) and Ca(2+) transient amplitudes in hiPSC-CM syncytia"><entity charOffset="22-25" id="DDI-PubMed.27520758.s4.e0" text="SOF" /><entity charOffset="1-4" id="DDI-PubMed.27520758.s4.e1" text="AMIO" /><pair ddi="false" e1="DDI-PubMed.27520758.s4.e1" e2="DDI-PubMed.27520758.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s4.e1" e2="DDI-PubMed.27520758.s4.e0" /></sentence><sentence text=" This action resembled that of Ca(2+) channel blockers (CCBs) in the model, but CCBs did not substitute for AMIO in the DDI"><entity charOffset="108-111" id="DDI-PubMed.27520758.s5.e0" text="AMIO" /></sentence><sentence text=" AMIO analog dronedarone (DRON) did not substitute for, but competed with AMIO in the DDI"><entity charOffset="1-5" id="DDI-PubMed.27520758.s6.e0" text="AMIO" /><entity charOffset="13-24" id="DDI-PubMed.27520758.s6.e1" text="dronedarone" /><entity charOffset="26-30" id="DDI-PubMed.27520758.s6.e2" text="DRON" /><entity charOffset="74-78" id="DDI-PubMed.27520758.s6.e3" text="AMIO" /><pair ddi="false" e1="DDI-PubMed.27520758.s6.e0" e2="DDI-PubMed.27520758.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27520758.s6.e0" e2="DDI-PubMed.27520758.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s6.e0" e2="DDI-PubMed.27520758.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s6.e0" e2="DDI-PubMed.27520758.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27520758.s6.e1" e2="DDI-PubMed.27520758.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s6.e1" e2="DDI-PubMed.27520758.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s6.e1" e2="DDI-PubMed.27520758.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27520758.s6.e2" e2="DDI-PubMed.27520758.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s6.e2" e2="DDI-PubMed.27520758.s6.e3" /></sentence><sentence text=" Ryanodine and thapsigargin, decreasing intracellular Ca(2+) stores, and SEA-0400, a Na(+)/Ca(2+) exchanger-1 (NCX1) inhibitor, partially antagonized or suppressed DDI effects"><entity charOffset="1-10" id="DDI-PubMed.27520758.s7.e0" text="Ryanodine" /><entity charOffset="15-27" id="DDI-PubMed.27520758.s7.e1" text="thapsigargin" /><entity charOffset="73-81" id="DDI-PubMed.27520758.s7.e2" text="SEA-0400" /><pair ddi="false" e1="DDI-PubMed.27520758.s7.e0" e2="DDI-PubMed.27520758.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27520758.s7.e0" e2="DDI-PubMed.27520758.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s7.e0" e2="DDI-PubMed.27520758.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s7.e1" e2="DDI-PubMed.27520758.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s7.e1" e2="DDI-PubMed.27520758.s7.e2" /></sentence><sentence text=" Other agents affecting FP rate only exerted additive or subtractive effects, commensurate with their individual effects" /><sentence text=" We also describe an interaction between AMIO and MNI-1 on Cav1"><entity charOffset="41-48" id="DDI-PubMed.27520758.s9.e0" text="AMIO" /></sentence><sentence text="2 ion channels in an over-expressing HEK-293 cell line" /><sentence text=" MNI-1 enhanced Cav1" /><sentence text="2 channel inhibition by AMIO, but did not affect inhibition of Cav1"><entity charOffset="24-27" id="DDI-PubMed.27520758.s12.e0" text="AMIO" /></sentence><sentence text="2 by DRON, verapamil, nifedipine, or diltiazem"><entity charOffset="5-9" id="DDI-PubMed.27520758.s13.e0" text="DRON" /><entity charOffset="11-20" id="DDI-PubMed.27520758.s13.e1" text="verapamil" /><entity charOffset="22-32" id="DDI-PubMed.27520758.s13.e2" text="nifedipine" /><entity charOffset="37-46" id="DDI-PubMed.27520758.s13.e3" text="diltiazem" /><pair ddi="false" e1="DDI-PubMed.27520758.s13.e0" e2="DDI-PubMed.27520758.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27520758.s13.e0" e2="DDI-PubMed.27520758.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s13.e0" e2="DDI-PubMed.27520758.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s13.e0" e2="DDI-PubMed.27520758.s13.e3" /><pair ddi="false" e1="DDI-PubMed.27520758.s13.e1" e2="DDI-PubMed.27520758.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27520758.s13.e1" e2="DDI-PubMed.27520758.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s13.e1" e2="DDI-PubMed.27520758.s13.e3" /><pair ddi="false" e1="DDI-PubMed.27520758.s13.e2" e2="DDI-PubMed.27520758.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27520758.s13.e2" e2="DDI-PubMed.27520758.s13.e3" /></sentence><sentence text=" Our data in hiPSC-CMs indicate that HCV-NI agents such as SOF and MNI-1 interact with key intracellular Ca(2+)-handling mechanisms"><entity charOffset="59-67" id="DDI-PubMed.27520758.s14.e0" text="SOF" /></sentence><sentence text=" Additional study in a Cav1" /><sentence text="2 HEK-293 cell-line suggests that HCV-NIs potentiate the inhibitory action of AMIO on L-type Ca(2+) channels"><entity charOffset="78-80" id="DDI-PubMed.27520758.s16.e0" text="AMIO" /></sentence><sentence text="" /></document>